Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zoledronic acid 4mg/5ml solution for infusion vials
0606020V0AAABAB
|
Zoledronic acid | Zoledronic acid | Endocrine System | 6 |
|
Zoledronic acid 4mg/100ml solution for infusion bottles
0606020V0AAADAD
|
Zoledronic acid | Zoledronic acid | Endocrine System | 4 |
|
Zoledronic acid 4mg/100ml solution for infusion vials
0606020V0AAAEAE
|
Zoledronic acid | Zoledronic acid | Endocrine System | 3 |
|
Zoledronic acid 5mg/100ml solution for infusion bottles
0606020V0AAACAC
|
Zoledronic acid | Zoledronic acid | Endocrine System | 3 |
|
Zoledronic acid 5mg/100ml solution for infusion vials
0606020V0AAAFAF
|
Zoledronic acid | Zoledronic acid | Endocrine System | 1 |
|
Aclasta 5mg/100ml solution for infusion bottles
0606020V0BCAAAC
|
Aclasta | Zoledronic acid | Endocrine System | No data available |
|
Zerlinda 4mg/100ml infusion bags
0606020V0BDAAAD
|
Zerlinda | Zoledronic acid | Endocrine System | No data available |
|
Zoledronic acid 4mg inf vials
0606020V0AAAAAA
|
Zoledronic acid | Zoledronic acid | Endocrine System | No data available |
|
Zoledronic acid 5mg/100ml infusion bags
0606020V0AAAGAG
|
Zoledronic acid | Zoledronic acid | Endocrine System | No data available |
|
Zometa 4mg inf vials
0606020V0BBAAAA
|
Zometa | Zoledronic acid | Endocrine System | No data available |
|
Zometa 4mg/100ml solution for infusion bottles
0606020V0BBACAD
|
Zometa | Zoledronic acid | Endocrine System | No data available |
|
Zometa 4mg/5ml solution for infusion vials
0606020V0BBABAB
|
Zometa | Zoledronic acid | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.